2021 Global CDMO Enterprise TOP10 and Gradient Distribution Map

The CXO industry is one of the pharmaceutical sub-sectors with the highest degree of internationalization.
The history of the development of foreign CXO giants can be said to be a history of mergers and acquisitions, especially small European countries such as Lonza, Recipharm, Siegfried Group, etc.
, to a large extent rely on overseas mergers and acquisitions to gradually grow into one of the international giants.
Therefore, when we are studying and analyzing this industry, we should stand in front of the globe and look at the development of the entire industry and the company from a global perspective.
In recent years, we have seen that domestic CXO companies such as WuXi, Kanglong Chemical, Gloria and Proton have set foot overseas.

Top 10 global CDMO companiesTop 10 global CDMO companiesTop 10 global CDMO companiesTop 10 global CDMO companies

From the table below, we can see that Lonza ranks first, and China's WuXi (WuXi AppTec + WuXi Biologics) has already occupied the second place in the world.

In Top10, two Asian faces, European companies accounted for the majority.

Data source: company financial report/pharmaceutical circle compilation; among them, Catalent, FAREVASA, Delpharm, Aenova are 19 years of data, BI only counts the business of CDMO; Patheon does not have the latest data; the exchange rate is in accordance with the latest

In terms of growth rate, WuXi ranked first.

In terms of revenue scale, WuXi and Lonza still have a gap of nearly US$1.
5 billion.

Source: Compiled by Pharmaceutical Circle; Patheon's revenue in 2016 was approximately US$1.

9 billion, and was acquired by Thermo Fisher Scientific in 2017.
There is no latest separate data yet to consider the ranking.

Global CDMO Enterprise Gradient RankingGlobal CDMO Enterprise Gradient RankingGlobal CDMO Enterprise Gradient RankingGlobal CDMO Enterprise Gradient Ranking

There are some non-listed companies abroad whose financial data is not regularly disclosed, but their strength cannot be ignored.

It can be seen from the following gradient distribution that there are not many CDMO heads in my country, and many of them have revenues of less than US$500 million, most of which are around US$100 million.
There are many outstanding companies among unlisted companies.
If you are interested, you can refer to the "China Pharmaceutical CDMO Industry Map in 2021"-the echelon ranking and distribution.

Source: Financial Report/Pharmaceutical Circle Production Note: This chart only considers companies with public financial data, and some outstanding unlisted companies are not included.

Comments on some foreign companiesComments on some foreign companiesComments on some foreign companiesComments on some foreign companies

In terms of regions, the European CDMO industry should be the number one in the world.

We select some featured companies to comment as follows:

In 1897, Lonza was born in the Swiss Alps.

So far, the business has spread to three continents around the world.
We have about 14,000 full-time employees, and their efficient team and each employee have made extraordinary changes to our business, the region and the country where we are located.
In 2020, the company's sales reached 4.
5 billion Swiss francs, and the core business's earnings before interest, taxes, depreciation and amortization (EBITDA) reached 1.
4 billion Swiss francs.

Founded in 1974, Patheon is headquartered in Durham, North Carolina, USA and Amsterdam, Netherlands.

It is a leading global supplier of outsourced medicine (CDMO), integrating R&D, production, manufacturing and service.
Thermo Fisher Scientific spent $7.
2 billion to acquire Patheon in 2017, including $2 billion in net debt.
Patheon has advanced production bases in North America and Europe, with nearly 9,000 employees worldwide.
The company's 2016 revenue was approximately $1.
9 billion, and it was incorporated into Thermo Fisher's laboratory products and services division.

Boehringer Ingelheim was founded in 1885 as a family business.

At present, the company's approximately 52,000 employees provide services for more than 130 markets in the three business areas of human pharmaceuticals, animal health and biopharmaceutical contract manufacturing.
In 2020, net sales of human medicines were 14.
42 billion euros, a year-on-year increase of 5.
8% (adjusted for exchange rate changes), accounting for 74% of total net sales, and R&D investment of 3.
28 billion euros, accounting for 22.
8% of net sales .

Source: Boehringer Ingelheim Annual Report

The animal health business performed well in 2020, with a year-on-year growth of 5% (year-on-year growth adjusted for exchange rate changes) and net sales of 4.

12 billion euros.
The company completed several acquisitions in 2020, involving companies in the veterinary and pet-related fields.
The company disclosed that 60% of the top 20 pharmaceutical companies and innovative biotechnology companies are customers of Boehringer Ingelheim’s CDMO business, and the brand’s trademark is Boehringer Ingelheim BioXcellenceTM.
In 2020, the net sales of the biopharmaceutical business was 837 million euros, an increase of 6.
6% year-on-year (year-on-year adjusted for exchange rate changes).
Outlook for 2021: Boehringer Ingelheim expects comparable net sales to increase slightly year-on-year.

Recipharm is the world's leading pharmaceutical contract development and manufacturing organization (CDMO).
It was established in Sweden in 1995, and in 2001, the Recipharm brand was established for the growing contract manufacturing part of the Recip business.
Between 2001 and 2007, six more factories were acquired.
These factories have increased production capacity, new advanced technologies, more diversified dosage forms, and a growing customer network.
In 2007, in order to adapt to the ever-changing market, the company decided to fully commit to outsourcing business.
Through further acquisitions to develop the'Recipharm' brand, established the position of pure CDMO.
2015-2020 successive acquisitions of multiple CDMO companies, in February 2020, Recipharm completed the largest acquisition to date.
The acquisition of Consort Medical, a UK-listed company, makes Recipharm one of the world's largest CDMOs in terms of revenue.
It currently has approximately 30 manufacturing and development facilities in Europe, India, Israel and North America, with 8,666 employees.

Siegfried Group is a global life science company with sales of 845.
1 million Swiss francs in fiscal year 2020.
As of December 31, 2020, it has approximately 2,500 employees in nine regions on three continents.
After taking over the two locations in Spain on January 1, 2021, this number has increased to approximately 3,500 employees.
Siegfried's business involves the production of APIs, intermediates, and preparations (tablets, capsules, sterile vials, ampoules, ointments, etc.
), and provides development services.
In 2020, the company acquired two large pharmaceutical production bases from Novartis in Barcelona.
As part of the acquisition, Novartis reached a long-term manufacturing and supply agreement, and Novartis promised to purchase a large number of important products from these two factories.

Delpharm was established in 1988 and has 17 factories and 4700 employees.
The company's official website disclosed revenue of 800 million euros in 2019.
In 1994, Delpharm acquired the Brétigny factory, Roche Synthex (specializing in the production of solid formulations).
The company acquired Pfizer Pharmaceutical's Evreux plant in 2002, thereby increasing its solid dosage production capacity.
Subsequently, it acquired the factories of major multinational pharmaceutical companies such as Bayer, Pfizer and Sanofi.
Among them, 5 factories were acquired in 2019.

For the fiscal year ending March 31, 2020, Fuji Group’s global revenue was 21 billion U.
S.
dollars.
FUJIFILM Diosynth Biotechnologies is a Biologics Contract Development and Manufacturing Organization (CDMO) located in Teesside, UK; RTP, North Carolina; College Station, Texas; and Hillerød, Denmark.
FUJIFILM Diosynth Biotechnologies has more than 30 years of experience in the development and manufacturing of recombinant proteins, vaccines, monoclonal antibodies, macromolecules, viral products, and medical technology expressed in a variety of microorganisms, mammals, and host/virus systems.
Tokyo, March 19, 2021-Fujifilm (President: Sukeno Kenji) announced that it has selected Holly Springs in North Carolina as its new large-scale cell culture production base in the United States, investing more than US$2 billion to build the largest North American End-to-end cell culture biopharmaceutical CDMO factory.

Aenova was established in Germany in 2008 as a merger of the drug companies Dragenopharm and Swiss Caps, forming the core of the group.
In 2012, the Temmler Group was acquired and Haupt Pharma was acquired in early 2014.
Since 2012, Aenova has been owned by private equity firm BCPartners.
Aenova Group is a leading global contract manufacturer and development service provider in the pharmaceutical and healthcare industries.
The service includes all dosage forms and potency levels (from nutrient solutions to high-activity drugs) in 15 locations in Europe and the United States.
End manufacturing and development, with 4,500 employees.

A global, independent and family group founded by Bernard Fraisse in 1990.
In 2019, the turnover reached 1.
81 billion euros, with 12,000 employees in 39 production sites.
On December 1, 2020, Fareva Group has completed the acquisition of two aseptic production bases in Idron and Saint-Julien-en-Genevois in France from Pierre-Fabre Group.
This acquisition reinforces Fareva's strategy of investing in major areas of the oncology field to develop and manufacture oncology products.

Almac Group is a mature contract development and manufacturing organization that provides a wide range of integrated services for the global pharmaceutical and biotechnology fields throughout the drug development life cycle.
The scope of services includes research and development, biomarker discovery, development and commercialization, API manufacturing, formulation development, clinical trial supply, IRT (IVRS/IWRS) to commercial-scale manufacturing.
This international company is a private company that has grown organically in the past five years and now employs more than 5,600 highly skilled personnel in 18 factories including Europe, the United States and Asia.

to sum upto sum upto sum upto sum up

From the ranking point of view, Chinese companies have indeed entered the forefront of the global rankings, but only WuXi is in the top 10.
There is a fault in the middle, and most of the remaining domestic CDMO companies are still outside the world's 10 or even 100.
In the future, we can rely on the domestic base camp market to accumulate experience and capital, and actively expand overseas.
Like Europe, our CDMO enterprise can also blossom globally.